TrialEpilepsia2022

A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.

Pasquale Striano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.